Home
VTYX
VTYX News

Latest Ventyx Biosciences Inc. (VTYX) News on June 1, 2025

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire

4 days ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

Spotlight On 3 Penny Stocks With Market Caps Under $500M

Simply Wall St.

11 days ago

Spotlight On 3 Penny Stocks With Market Caps Under $500M

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

GlobeNewswire

23 days ago

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Great week for Ventyx Biosciences, Inc. (NASDAQ:VTYX) institutional investors after losing 70% over the previous year

Simply Wall St.

a month ago

Great week for Ventyx Biosciences, Inc. (NASDAQ:VTYX) institutional investors after losing 70% over the previous year

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

GlobeNewswire

2 months ago

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

GlobeNewswire

3 months ago

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

GlobeNewswire

3 months ago

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswire

4 months ago

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ventyx Biosciences highlights its 2025 pipeline strategy

TipRanks

5 months ago

Ventyx Biosciences highlights its 2025 pipeline strategy

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

GlobeNewswire

5 months ago

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

We're Keeping An Eye On Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Simply Wall St.

5 months ago

We're Keeping An Eye On Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k

Simply Wall St.

6 months ago

Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 11/26/2024

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures

Simply Wall St.

6 months ago

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures

Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress

TipRanks

7 months ago

Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

GlobeNewswire

7 months ago

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

MT Newswires

7 months ago

Oppenheimer Trims Ventyx Biosciences Price Target to $9 From $10, Maintains Outperform Rating

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress

GlobeNewswire

7 months ago

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress

These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts

TipRanks

7 months ago

These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

GlobeNewswire

8 months ago

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

VTYX Stock Rises on Strategic Equity Investment Deal With SNY

Zacks

8 months ago

VTYX Stock Rises on Strategic Equity Investment Deal With SNY

Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal

Pharmaceutical Technology

8 months ago

Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal

MT Newswires

8 months ago

Ventyx Biosciences Shares Up as Sanofi to Invest $27 Million

Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi

GlobeNewswire

8 months ago

Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi

MT Newswires

9 months ago

Ventyx Biosciences Doses First Patient in Phase 2a Parkinson's Drug Trial

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

GlobeNewswire

9 months ago

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

MT Newswires

9 months ago

Ventyx Biosciences Finance Chief Martin Auster Steps Down

Ventyx Biosciences Announces Departure of Chief Financial Officer

GlobeNewswire

9 months ago

Ventyx Biosciences Announces Departure of Chief Financial Officer

Novo builds heart failure case for semaglutide; Ventyx CFO departs

BioPharma Dive

9 months ago

Novo builds heart failure case for semaglutide; Ventyx CFO departs

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

GlobeNewswire

9 months ago

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

GlobeNewswire

10 months ago

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx scraps TYK2 inhibitor after Phase II Crohn’s defeat

Pharmaceutical Technology

10 months ago

Ventyx scraps TYK2 inhibitor after Phase II Crohn’s defeat

Ventyx scraps TYK2 inhibitor after Phase II Crohn’s defeat

Clinical Trials Arena

10 months ago

Ventyx scraps TYK2 inhibitor after Phase II Crohn’s defeat

MT Newswires

10 months ago

Top Midday Decliners

MT Newswires

10 months ago

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT Newswires

10 months ago

Ventyx Biosciences Shares Fall After VTX958 Trial for Crohn's Fails to Meet Primary Endpoint

Ventyx’s TYK2 drug suffers second setback

BioPharma Dive

10 months ago

Ventyx’s TYK2 drug suffers second setback

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease

GlobeNewswire

10 months ago

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

Simply Wall St.

a year ago

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

The Government of Canada invests over $3.3 million in nine grassroots, community projects to curb greenhouse gas emissions and fight climate change

CNW Group

a year ago

The Government of Canada invests over $3.3 million in nine grassroots, community projects to curb greenhouse gas emissions and fight climate change

CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS

GlobeNewswire

a year ago

CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS

GlobeNewswire

a year ago

Onfolio Holdings Inc. To Acquire DDS Rank Business

Thor Equities Group Advances Cross-Border Logistics Strategy with Key Acquisition

GlobeNewswire

a year ago

Thor Equities Group Advances Cross-Border Logistics Strategy with Key Acquisition

As Nvidia Teases Mega Milestone, This AI Stock Targets Early Breakout

Investor's Business Daily

a year ago

As Nvidia Teases Mega Milestone, This AI Stock Targets Early Breakout

See's Candies® Launches New Scotchmallow® Littles

PR Newswire

a year ago

See's Candies® Launches New Scotchmallow® Littles

Biden announces $225 mn in new aid for Ukraine at Paris talks with Zelensky

AFP

a year ago

Biden announces $225 mn in new aid for Ukraine at Paris talks with Zelensky

Stock futures slip as markets digest hot jobs data

Yahoo Finance Video

a year ago

Stock futures slip as markets digest hot jobs data

MT Newswires

a year ago

Oppenheimer Adjusts Ventyx Biosciences Price Target to $10 From $12, Maintains Outperform Rating

MT Newswires

a year ago

Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

GlobeNewswire

a year ago

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

GlobeNewswire

a year ago

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

MT Newswires

a year ago

Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

GlobeNewswire

a year ago

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

GlobeNewswire

a year ago

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

GlobeNewswire

a year ago

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

What Makes Ventyx Biosciences (VTYX) a New Buy Stock

Zacks

a year ago

What Makes Ventyx Biosciences (VTYX) a New Buy Stock

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

GlobeNewswire

a year ago

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

NodThera says inflammation drug has positive effect in Parkinson’s

BioPharma Dive

a year ago

NodThera says inflammation drug has positive effect in Parkinson’s

Ventyx Biosciences Announces $100 Million Private Placement of Common Stock

GlobeNewswire

a year ago

Ventyx Biosciences Announces $100 Million Private Placement of Common Stock

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

GlobeNewswire

a year ago

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024

GlobeNewswire

a year ago

Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

GlobeNewswire

a year ago

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)

GlobeNewswire

a year ago

Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)

Weight-Loss Drug Hype Sends Biotech Ventyx’s Stock Soaring on Rival’s Data

Bloomberg

a year ago

Weight-Loss Drug Hype Sends Biotech Ventyx’s Stock Soaring on Rival’s Data

Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire

a year ago

Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

a year ago

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?

Associated Press Finance

a year ago

First Community Bancshares: Q4 Earnings Snapshot

First Community Bankshares, Inc. Announces Fourth Quarter 2023 Results and Quarterly Cash Dividend

GlobeNewswire

a year ago

First Community Bankshares, Inc. Announces Fourth Quarter 2023 Results and Quarterly Cash Dividend

Rekor Systems Secures Five-Year Traffic Counting Contract With Gwinnett GA Department of Transportation

ACCESSWIRE

a year ago

Rekor Systems Secures Five-Year Traffic Counting Contract With Gwinnett GA Department of Transportation

Why WW International Stock Plummeted by 9% Today

Motley Fool

a year ago

Why WW International Stock Plummeted by 9% Today

Amundi US Declares Monthly Distributions for Pioneer Closed-End Funds

Business Wire

a year ago

Amundi US Declares Monthly Distributions for Pioneer Closed-End Funds

Third Coast Bancshares, Inc. Announces 2023 Fourth Quarter and Full Year Earnings Release and Conference Call Schedule

PR Newswire

a year ago

Third Coast Bancshares, Inc. Announces 2023 Fourth Quarter and Full Year Earnings Release and Conference Call Schedule

Ventyx Biosciences Inc CEO Raju Mohan Sells 58,860 Shares

GuruFocus.com

a year ago

Ventyx Biosciences Inc CEO Raju Mohan Sells 58,860 Shares

CFO Houte Van Sells 10,906 Shares of Nurix Therapeutics Inc

GuruFocus.com

a year ago

CFO Houte Van Sells 10,906 Shares of Nurix Therapeutics Inc

Is It Time To Consider Buying Codexis, Inc. (NASDAQ:CDXS)?

Simply Wall St.

a year ago

Is It Time To Consider Buying Codexis, Inc. (NASDAQ:CDXS)?

Pleasing Signs As A Number Of Insiders Buy NexPoint Real Estate Finance Stock

Simply Wall St.

a year ago

Pleasing Signs As A Number Of Insiders Buy NexPoint Real Estate Finance Stock

7 Stocks That Should Be on Your Christmas List This Year

InvestorPlace

2 years ago

7 Stocks That Should Be on Your Christmas List This Year

Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire

2 years ago

Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire

2 years ago

RGC Resources, Inc. Reports 2023 Earnings

Consumer Portfolio Services, Inc. (NASDAQ:CPSS) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Consumer Portfolio Services, Inc. (NASDAQ:CPSS) Q3 2023 Earnings Call Transcript

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

GlobeNewswire

2 years ago

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference

GlobeNewswire

2 years ago

Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference

Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress

GlobeNewswire

2 years ago

Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress

Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround

Zacks

2 years ago

Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Kaltura Inc Earnings Call

Hallador Energy Company (NASDAQ:HNRG) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Hallador Energy Company (NASDAQ:HNRG) Q3 2023 Earnings Call Transcript

Kaltura Announces Financial Results for Third Quarter 2023

GlobeNewswire

2 years ago

Kaltura Announces Financial Results for Third Quarter 2023

Ventyx Crashes 81% After Scrapping Two Studies On A Psoriasis Treatment Flop

Investor's Business Daily

2 years ago

Ventyx Crashes 81% After Scrapping Two Studies On A Psoriasis Treatment Flop

Ventyx revises TYK2 drug plans after lackluster study data

BioPharma Dive

2 years ago

Ventyx revises TYK2 drug plans after lackluster study data

Share on Social Networks: